Abeona Therapeutics (ABEO) Expected to Announce Earnings on Wednesday

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.19. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Abeona Therapeutics Price Performance

Shares of ABEO stock opened at $5.63 on Wednesday. The stock's fifty day simple moving average is $5.15 and its 200 day simple moving average is $5.57. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm has a market cap of $274.74 million, a price-to-earnings ratio of -2.09 and a beta of 1.68. Abeona Therapeutics has a one year low of $3.93 and a one year high of $7.32.

Insider Activity

In other news, CEO Vishwas Seshadri sold 25,000 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $4.78, for a total transaction of $119,500.00. Following the transaction, the chief executive officer now owns 1,355,322 shares of the company's stock, valued at $6,478,439.16. This represents a 1.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 6.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

ABEO has been the topic of a number of recent analyst reports. StockNews.com raised Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, March 24th. HC Wainwright boosted their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, April 30th. Finally, Oppenheimer initiated coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Abeona Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $18.75.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.